At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 116 enrolled
Drug / intervention
OLP-1002 (Test): Part A, Single Ascending Dose +3 moredrug
Likely dose
OLP-1002 (Test): Part A, Single Ascending Dose 1.2 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
OLP-1002 - A First-in-human, Double-blind, Placebo-controlled, Single and Multiple Subcutaneous Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Male and Female Subjects
In Brief
A Early Phase 1 clinical trial evaluating OLP-1002 (Test): Part A, Single Ascending Dose, OLP-1002 (Test): Part B, Multiple Ascending Dose, and 2 other interventions for Pain. Completed, enrolled 116 participants across 1 site.
Detailed Summary
The primary objective of the study is to assess the safety and tolerability of single and multiple subcutaneous doses of OLP-1002 in healthy subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited Kingdom
Collaborators--
Timeline
Early Ph 1CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedDec 2018
Primary CompletionOct 2020
TodayJul 2026
First PostedDec 3, 2018
Enrollment StartNov 21, 2018
Primary CompletionOct 16, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.6 years ago
Interventions
OLP-1002 (Test): Part A, Single Ascending Dosedrug
Subcutaneous Injection: 30 ng, 120 ng, 400 ng, 1.2 µg, 3 µg, 6 µg, 12 µg, 20 µg, 40 μg, 80 μg, 160 μg
OLP-1002 (Test): Part B, Multiple Ascending Dosedrug
Subcutaneous Injection: 5 x 2 μg, 5 x 5 μg, 5 x 10 μg, 5 x 20 μg, 5 x 40 μg, 5 x 80 μg
Placebo: Placebo Part A, Single Ascending Doseother
Subcutaneous Injection: Placebo
Placebo: Placebo Part B, Multiple Ascending Doseother
Subcutaneous Injection: Placebo x 5